| Variable | Overall N = 2921 |
No early TB N = 2631 |
Early TB N = 291 |
p-value2 |
|---|---|---|---|---|
| Age, years | 28 (21, 37) | 27 (21, 35) | 35 (28, 40) | 0.024 |
| BMI | 22.0 (19.7, 25.2) | 22.0 (19.7, 25.4) | 23.1 (21.1, 24.3) | >0.9 |
| Sex | 0.12 | |||
| Male | 162 (55%) | 142 (54%) | 20 (69%) | |
| Female | 130 (45%) | 121 (46%) | 9 (31%) | |
| HIV status | 0.007 | |||
| HIV− | 260 (89%) | 239 (91%) | 21 (72%) | |
| HIV+ | 32 (11%) | 24 (9.1%) | 8 (28%) | |
| Prior TB history | 0.014 | |||
| No prior TB | 276 (95%) | 252 (96%) | 24 (83%) | |
| Prior TB | 16 (5.5%) | 11 (4.2%) | 5 (17%) | |
| Baseline TB status (Trace counted as TB) | <0.001 | |||
| Negative | 272 (93%) | 262 (100%) | 10 (34%) | |
| TB | 19 (6.5%) | 0 (0%) | 19 (66%) | |
| Baseline symptoms | 0.3 | |||
| Asymptomatic | 261 (89%) | 233 (89%) | 28 (97%) | |
| Symptomatic | 31 (11%) | 30 (11%) | 1 (3.4%) | |
| Cavitation | <0.001 | |||
| Absent | 274 (94%) | 255 (97%) | 19 (66%) | |
| Present | 18 (6.2%) | 8 (3.0%) | 10 (34%) | |
| Consolidation | <0.001 | |||
| Absent | 272 (93%) | 255 (97%) | 17 (59%) | |
| Present | 20 (6.8%) | 8 (3.0%) | 12 (41%) | |
| Fibrosis/scarring | <0.001 | |||
| Absent | 204 (70%) | 195 (74%) | 9 (31%) | |
| Present | 88 (30%) | 68 (26%) | 20 (69%) | |
| Calcified granuloma | <0.001 | |||
| Absent | 268 (92%) | 247 (94%) | 21 (72%) | |
| Present | 24 (8.2%) | 16 (6.1%) | 8 (28%) | |
| Bronchiectasis | <0.001 | |||
| Absent | 253 (87%) | 238 (90%) | 15 (52%) | |
| Present | 39 (13%) | 25 (9.5%) | 14 (48%) | |
| Ground-glass opacity | 0.2 | |||
| Absent | 261 (89%) | 237 (90%) | 24 (83%) | |
| Present | 31 (11%) | 26 (9.9%) | 5 (17%) | |
| Tree-in-bud | <0.001 | |||
| Absent | 271 (93%) | 253 (96%) | 18 (62%) | |
| Present | 21 (7.2%) | 10 (3.8%) | 11 (38%) | |
| Pleural thickening | <0.001 | |||
| Absent | 265 (91%) | 248 (94%) | 17 (59%) | |
| Present | 27 (9.2%) | 15 (5.7%) | 12 (41%) | |
| Atelectasis | 0.002 | |||
| Absent | 281 (96%) | 257 (98%) | 24 (83%) | |
| Present | 11 (3.8%) | 6 (2.3%) | 5 (17%) | |
| Pneumothorax | >0.9 | |||
| Absent | 290 (99%) | 261 (99%) | 29 (100%) | |
| Present | 2 (0.7%) | 2 (0.8%) | 0 (0%) | |
| Pleural effusion | >0.9 | |||
| Absent | 290 (99%) | 261 (99%) | 29 (100%) | |
| Present | 2 (0.7%) | 2 (0.8%) | 0 (0%) | |
| Hilar/mediastinal lymphadenopathy | <0.001 | |||
| Absent | 286 (98%) | 262 (100%) | 24 (83%) | |
| Present | 6 (2.1%) | 1 (0.4%) | 5 (17%) | |
| Nodules/masses | <0.001 | |||
| Absent | 232 (79%) | 218 (83%) | 14 (48%) | |
| Present | 60 (21%) | 45 (17%) | 15 (52%) | |
| Multiple lesion types | <0.001 | |||
| Absent | 221 (76%) | 212 (81%) | 9 (31%) | |
| Present | 71 (24%) | 51 (19%) | 20 (69%) | |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test | ||||